Ascentage Pharma Group InternatAAPG stock score: 45/100

$12.44 · -4.40% · Scored Nov 19, 2026

Technical
22
Fundamental
51
News
51

The reading

Ascentage Pharma Group Internat (AAPG) scores 45 out of 100, which reads weak, higher than 35% of Healthcare stocks and 33% of the 4,118 US stocks we score.

The composite weights fundamentals 80% and technicals 20%: fundamentals read 51, technicals 22.

Among the fundamentals, Price Target at 100 and Revenue Growth (Annual) at 100 score highest, while Earnings Profitability (Quarterly) at 0 weighs the most against it.

On the daily chart, trend-following indicators average 13 and contrarian oscillators 71 — a split worth reading before trusting the technical total.

News sentiment is neutral at 51; it is shown, not counted in the composite.

Since Aug 24, 2026 the composite has ranged from 34 to 48, and it is up 10 points over the period.

About Ascentage Pharma Group Internat

Ascentage Pharma (AAPG) is a biotechnology company based in Suzhou, China, that develops and sells medicines for blood cancers and other cancers. Its first approved drug, olverembatinib, is a third-generation BCR-ABL1 inhibitor approved in China for chronic myeloid leukemia, including drug-resistant disease. Its second, lisaftoclax, is a Bcl-2 inhibitor approved in China for previously treated chronic lymphocytic leukemia and small lymphocytic lymphoma. It is running global registrational trials of both drugs, including lisaftoclax in several blood cancers, and developing other candidates such as APG-5918. Ascentage earns money from sales of its approved drugs in China, which it markets with a commercial partner, and from licensing and collaboration agreements with larger drugmakers, including an option deal with Takeda for olverembatinib outside China. Its shares trade in Hong Kong and, as American depositary shares, on Nasdaq.

Ascentage competes with larger companies that sell treatments for leukemia and lymphoma, including Novartis, AbbVie and BeOne Medicines. Its edge rests on in-house research in protein-protein interactions and apoptosis, a pair of drugs already approved in China and data from patients who failed earlier therapies. Investors who follow AAPG stock tend to watch results from its global registrational trials and regulatory filings outside China. Sales of olverembatinib and lisaftoclax are closely followed. Partnership milestones, cash runway, operating expenses and trade relations between the United States and China are other factors.

What’s driving the score

The strongest and weakest of the scorers that count toward AAPG’s composite. Each returns 0–100, higher is more bullish — including metrics where low is good, like P/E.

Fundamental

51

Pulling it up

  • Price target score compares the current stock price to analyst consensus targets.

  • Annual revenue growth tracks year-over-year sales expansion.

  • How the latest quarter's revenue compares with the average of the last four, plus a bonus for steady quarterly revenue.

Holding it back

  • Earnings Profitability (Quarterly) measures recent profitability using trailing 12-month quarterly data.

  • Net income growth against the same quarter a year earlier, weighted toward the latest quarter.

  • Absolute profitability: whether the company is profitable, its net margin against the sector range, and how consistently it has been profitable over three years.

37 weighted scorers; 2 had no data today and are left out rather than counted as zero.

Technical · daily

19

Pulling it up

  • Bollinger Bands (20-period) plot standard deviations above and below a moving average.

  • Bollinger Bands (50-period) measure where price sits between bands two standard deviations around its 50-period average.

  • Williams %R (28-period) places the close within the last 28 periods' high-low range.

Holding it back

  • S&P 500 52-week comparison evaluates the stock's annual performance relative to the broader market.

  • Candlestick patterns recognize specific price formations that historically suggest continuation or reversal.

  • The price change over the last 52 weeks.

62 weighted scorers; 3 had no data today and are left out rather than counted as zero.

News · shown, not counted

Global News
51

Technical score by timeframe

ChartScoreWeight
Hourly331
Daily193
Weekly222

Composite score, last 90 days

05010045Aug 24, 2026Nov 20, 2026Aug 24, 2026: 35Aug 25, 2026: 36Aug 26, 2026: 36Aug 27, 2026: 35Aug 28, 2026: 41Aug 29, 2026: 38Aug 30, 2026: 39Aug 31, 2026: 38Sep 1, 2026: 36Sep 2, 2026: 37Sep 3, 2026: 36Sep 4, 2026: 37Sep 5, 2026: 38Sep 6, 2026: 38Sep 7, 2026: 37Sep 8, 2026: 38Sep 9, 2026: 38Sep 10, 2026: 37Sep 11, 2026: 36Sep 12, 2026: 35Sep 13, 2026: 35Sep 14, 2026: 35Sep 15, 2026: 35Sep 16, 2026: 35Sep 17, 2026: 34Sep 18, 2026: 36Sep 19, 2026: 36Sep 20, 2026: 36Sep 21, 2026: 36Sep 22, 2026: 37Sep 23, 2026: 38Sep 24, 2026: 38Sep 25, 2026: 38Sep 26, 2026: 36Sep 27, 2026: 36Sep 28, 2026: 35Sep 29, 2026: 36Sep 30, 2026: 37Oct 1, 2026: 39Oct 2, 2026: 38Oct 3, 2026: 36Oct 4, 2026: 37Oct 5, 2026: 36Oct 6, 2026: 36Oct 7, 2026: 39Oct 8, 2026: 37Oct 9, 2026: 37Oct 10, 2026: 37Oct 11, 2026: 37Oct 12, 2026: 37Oct 13, 2026: 37Oct 14, 2026: 38Oct 15, 2026: 37Oct 16, 2026: 36Oct 17, 2026: 39Oct 18, 2026: 39Oct 19, 2026: 38Oct 20, 2026: 39Oct 21, 2026: 40Oct 22, 2026: 41Oct 23, 2026: 37Oct 24, 2026: 39Oct 25, 2026: 39Oct 26, 2026: 39Oct 27, 2026: 40Oct 28, 2026: 38Oct 29, 2026: 37Oct 30, 2026: 38Oct 31, 2026: 37Nov 2, 2026: 36Nov 3, 2026: 36Nov 4, 2026: 36Nov 5, 2026: 38Nov 6, 2026: 38Nov 7, 2026: 39Nov 8, 2026: 39Nov 11, 2026: 39Nov 13, 2026: 48Nov 14, 2026: 47Nov 16, 2026: 48Nov 18, 2026: 45Nov 19, 2026: 46Nov 20, 2026: 45
Show the daily numbers
DateComposite
Nov 20, 202645
Nov 19, 202646
Nov 18, 202645
Nov 16, 202648
Nov 14, 202647
Nov 13, 202648
Nov 11, 202639
Nov 8, 202639
Nov 7, 202639
Nov 6, 202638
Nov 5, 202638
Nov 4, 202636
Nov 3, 202636
Nov 2, 202636
Oct 31, 202637
Oct 30, 202638
Oct 29, 202637
Oct 28, 202638
Oct 27, 202640
Oct 26, 202639
Oct 25, 202639
Oct 24, 202639
Oct 23, 202637
Oct 22, 202641
Oct 21, 202640
Oct 20, 202639
Oct 19, 202638
Oct 18, 202639
Oct 17, 202639
Oct 16, 202636
Oct 15, 202637
Oct 14, 202638
Oct 13, 202637
Oct 12, 202637
Oct 11, 202637
Oct 10, 202637
Oct 9, 202637
Oct 8, 202637
Oct 7, 202639
Oct 6, 202636
Oct 5, 202636
Oct 4, 202637
Oct 3, 202636
Oct 2, 202638
Oct 1, 202639
Sep 30, 202637
Sep 29, 202636
Sep 28, 202635
Sep 27, 202636
Sep 26, 202636
Sep 25, 202638
Sep 24, 202638
Sep 23, 202638
Sep 22, 202637
Sep 21, 202636
Sep 20, 202636
Sep 19, 202636
Sep 18, 202636
Sep 17, 202634
Sep 16, 202635
Sep 15, 202635
Sep 14, 202635
Sep 13, 202635
Sep 12, 202635
Sep 11, 202636
Sep 10, 202637
Sep 9, 202638
Sep 8, 202638
Sep 7, 202637
Sep 6, 202638
Sep 5, 202638
Sep 4, 202637
Sep 3, 202636
Sep 2, 202637
Sep 1, 202636
Aug 31, 202638
Aug 30, 202639
Aug 29, 202638
Aug 28, 202641
Aug 27, 202635
Aug 26, 202636
Aug 25, 202636
Aug 24, 202635

Key facts

Market cap
$1.2B
Sector
Healthcare
Industry
Biotechnology
Beta
0.77
Risk grade (1–10)
—
Next earnings
—

Questions

What is AAPG's stock rating today?

AAPG scores 45/100 (Weak) as of Nov 19, 2026: technical 22, fundamental 51, and news sentiment 51, which is shown but not counted. Scores are recomputed every night.

What does Ascentage Pharma Group Internat do?

Ascentage Pharma (AAPG) is a biotechnology company based in Suzhou, China, that develops and sells medicines for blood cancers and other cancers. Its first approved drug, olverembatinib, is a third-generation BCR-ABL1 inhibitor approved in China for chronic myeloid leukemia, including drug-resistant disease.

Is AAPG stock a buy?

The score is not a buy or sell recommendation. A 45 says the technical and fundamental signals we measure lean weak today, relative to every other stock scored the same way. Use the breakdown above to see why, and treat it as a starting point for your own research.

How is the AAPG score calculated?

99 weighted scorers feed it today: 37 fundamental, scored against Healthcare ranges, and 62 technical on the daily chart, with 3 timeframes blended into the technical total. Every scorer returns 0–100; missing data is left out, never counted as zero.

Scores are information, not investment advice. Computed from Yahoo Finance, Finnhub and Alpha Vantage data; technical indicators via TA-Lib. Past scores do not predict future returns.

Embed this score

A badge for a blog post, newsletter or README. It updates every night and links back here. More badges

AAPG stock score

HTML

<a href="https://stocksscores.com/stocks/aapg/"><img src="https://stocksscores.com/stocks/aapg/badge.svg" alt="AAPG stock score" height="20"></a>

Markdown

[![AAPG stock score](https://stocksscores.com/stocks/aapg/badge.svg)](https://stocksscores.com/stocks/aapg/)